Cart
sales@molnova.com
AZD6538
CAS No. 453566-30-8
AZD6538( —— )
Catalog No. M34170 CAS No. 453566-30-8
AZD6538 is an mGluR5 negative allosteric modulator used in the study of CNS-related diseases such as Alzheimer's disease.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 36 | In Stock |
|
| 10MG | 61 | In Stock |
|
| 25MG | 122 | In Stock |
|
| 50MG | 178 | In Stock |
|
| 100MG | 263 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAZD6538
-
NoteResearch use only, not for human use.
-
Brief DescriptionAZD6538 is an mGluR5 negative allosteric modulator used in the study of CNS-related diseases such as Alzheimer's disease.
-
DescriptionAZD6538 is an mGluR5 negative allosteric modulator used in the study of CNS-related diseases such as Alzheimer's disease.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayNeuroscience
-
TargetGluR
-
RecptorGluR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number453566-30-8
-
Formula Weight291.24
-
Molecular FormulaC15H6FN5O
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESN#CC=1C=NC(=CC1)C2=NOC(=N2)C=3C=C(F)C=C(C#N)C3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Memantine hydrochlor...
Memantine is an uncompetitive NMDA receptor antagonist. When using HEK293 cells express recombinant rat NMDA receptors, memantine shows inhibition of L-glutamate-mediated response with a dose- and voltage-dependent manner.
-
A-794282
A-794282 is a selective and potent mGlu1 receptor antagonist with analgesic activity and may be useful in the study of neurologic disorders.
-
Valiglurax
Valiglurax (VU2957), also known as VU0652957 and VU2957, is a potent, selective, CNS penetrant, and orally bioavailable mGlu4 PAM. VU2957 possessed attractive in vitro and in vivo pharmacological and DMPK properties across species.
